Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $10.00.

AMRX has been the subject of several analyst reports. Piper Sandler upped their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, November 11th. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, October 2nd. Finally, StockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th.

Amneal Pharmaceuticals Stock Up 2.4 %

Shares of Amneal Pharmaceuticals stock traded up $0.19 on Thursday, hitting $8.06. 1,447,903 shares of the company were exchanged, compared to its average volume of 1,067,320. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -11.85 and a beta of 1.10. The company has a 50-day moving average price of $8.23 and a 200 day moving average price of $8.03.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 17,410 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the completion of the transaction, the director now owns 2,031,476 shares of the company's stock, valued at $16,272,122.76. This trade represents a 0.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jason B. Daly sold 43,657 shares of the company's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares in the company, valued at $117,655.65. This represents a 76.16 % decrease in their position. The disclosure for this sale can be found here. 17.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the third quarter worth approximately $37,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at approximately $42,000. Quest Partners LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter worth approximately $84,000. Xponance Inc. acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $65,000. Finally, Quadrature Capital Ltd purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at $169,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.